Edition:
United States

NxStage Medical Inc (NXTM.OQ)

NXTM.OQ on NASDAQ Stock Exchange Global Select Market

22.78USD
26 May 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$22.78
Open
$22.78
Day's High
$22.91
Day's Low
$22.52
Volume
156,557
Avg. Vol
163,705
52-wk High
$30.80
52-wk Low
$18.28

Latest Key Developments (Source: Significant Developments)

NxStage Q1 revenue $96.8 million
Tuesday, 9 May 2017 08:16am EDT 

May 9 (Reuters) - NxStage Medical Inc ::NxStage reports first quarter financial results.Sees q2 2017 revenue $95 million to $97 million.Q1 revenue $96.8 million versus I/B/E/S view $95.3 million.NxStage Medical Inc - qtrly loss per share $ 0.02.NxStage Medical Inc - revising annual home revenue growth target to be between 10 to 13 pct for 2017 versus previous 15 pct target.NxStage Medical Inc - expect fy total company revenue in a range of $400 to $405 million.NxStage Medical Inc - company reaffirms total revenue guidance and profitability for 2017.NxStage Medical Inc - for q2 of 2017, company expects net loss in range of $1 to $3 million.Q2 revenue view $98.5 million -- Thomson Reuters I/B/E/S.Fy2017 revenue view $401.5 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S.  Full Article

NxStage reports Q4 revenue of $93 million
Tuesday, 28 Feb 2017 08:02am EST 

NxStage Medical Inc : NxStage reports fourth quarter and full-year 2016 financial results . Q4 revenue $93 million versus I/B/E/S view $91.8 million . Sees FY 2017 revenue $400 million to $405 million . NxStage Medical Inc - Company continues to target introduction of peritoneal dialysis system at end of 2017 . NxStage Medical Inc - Company is forecasting revenue between $95 and $97 million for Q1 of 2017 . NxStage Medical Inc - Company also expects to have positive net income for full fiscal year 2017 . Qtrly loss per share $0.02 . NxStage Medical Inc - Sees net loss in range of $1 to $3 million for Q1 of 2017 . Q4 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S .FY2017 revenue view $401.2 million -- Thomson Reuters I/B/E/S.  Full Article

NxStage Medical Inc raises FY 2015 guidance; gives Q4 2015 guidance
Tuesday, 3 Nov 2015 07:28am EST 

NxStage Medical Inc:Expects FY 2015 revenue to be between $332 and $333 million, versus its previously increased guidance for revenue to be at the high end of its range of $324 to $328 million.Now expects FY 2015 net loss to be between $15 and $16 million, versus its previous guidance of $18 to $20 million, which was revised from its original guidance of $20 to $24 million.For the Q4 2015, the Company expects revenue to be in a range of $86 and $87 million, and a net loss in the range of $2 to $3 million.FY 2015 revenue of $327.8 million and net loss of $(20.1) million - Thomson Reuters I/B/E/S.Q4 2015 revenue of $85.9 million and net loss of $(3.71) million - Thomson Reuters I/B/E/S.  Full Article

NxStage and Spindial announce partnership with Niguarda-Ca' Granda Hospital in Milan
Friday, 11 Sep 2015 07:00am EDT 

NxStage Medical Inc:Announces their new partnership with the Niguarda-Ca' Granda hospital in Milan, Italy to help assist hemodialysis patients, including both current NxStage patients and non-NxStage patients, who wish to travel to Milan.  Full Article

NxStage Medical Inc sees FY 2015 revenue guidance to achieve at high end of prior guidance, lowers net loss guidance; gives Q3 2015 revenue guidance above estimates, net loss guidance below estimates
Thursday, 6 Aug 2015 07:45am EDT 

NxStage Medical Inc:Expects Q3 2015 revenue to be between $82 million and $83 million.Q3 2015 net loss in the range of $4.5 million to $5.5 million.Net loss guidance reflects expectations for continued operating income from the Products Business offset by the Company's continued investment in NxStage Kidney Care.Q3 2015 revenue of $81.8 million and net loss of $5.9 million - Thomson Reuters I/B/E/S.Expects FY 2015 to achieve the top end of prior revenue guidance between $324 and $328 million.Now expects FY 2015 net loss guidance in a range of $18 to $20 million versus previous guidance of net loss in the range of $20 to $24 million.FY 2015 revenue of $327.6 million and net loss of $22.7 million - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Nxstage Medical announces FDA clearance for new system one hemodialysis system

* Nxstage Medical announces fda clearance for its new system one hemodialysis system